Nizatidine is a histamine type 2 receptor antagonist (H2 blocker) which is widely used for treatment of acid-peptic disease and heartburn. Nizatidine has been linked to rare instances of clinically apparent acute liver injury[3]. In rat and dog models, species in which the absorption, plasma half-life and routes of metabolism are similar to that of humans, nizatidine was three- to four-fold more active than cimetidine and was of similar potency to ranitidine. Nizatidine was well-tolerated in animals after both intravenous and oral administration and following single or repeated administration[4]. Nizatidine administration significantly improved both gastric emptying and clinical symptoms in FD (functional dyspepsia) patients with impaired gastric emptying[5]. Intravenous administration of nizatidine (0.3 - 3 mg/kg) enhanced the motility of the gastric antrum and duodenum during the digestive state. Gastric emptying of a solid test meal was accelerated by intraperitoneal administration of nizatidine (1 - 10 mg/kg) to the same extent as cisapride (0.1 - 1 mg/kg). Furthermore, nizatidine improved clonidine-induced delayed gastric emptying[6].
Brazil
... 展开 >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Rio de Janeiro, Brazil 收起 <<
United States, Minnesota
... 展开 >>
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Mayo Clinic
Rochester, Minnesota, United States, 55905 收起 <<
搜索
